ClinicalTrials.gg
RecruitingNCT07877714NBS3OMD22Updated Oct 16, 2026

Newborn Screening and Early Diagnosis of AADC Deficiency in the Ligurian Population

An observational study in Neurology, Aromatic Amino Acid Decarboxylase Deficiency and Pediatric Neurological Disorder, sponsored by Istituto Giannina Gaslini. Recruiting at 10 sites in Italy. Open to participants aged 0 Days to 3 Days. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Istituto Giannina Gaslini · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Oct 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16,000
Ages
0 Days to 3 Days
Sex
All
01

Study summary

Aromatic L-amino acid decarboxylase deficiency (AADC-D) is a rare genetic disorder that affects the production of neurotransmitters in the brain and can cause severe neurological and developmental problems. Early diagnosis may allow affected children to be referred promptly for specialist care and evaluation for available treatments, including gene therapy.

The purpose of this study is to develop a newborn screening protocol for AADC-D in the neonatal population of Liguria, Italy, and to estimate the incidence of the disease in this population. The study will also establish reference values for 3-O-methyldopa (3-OMD), a biochemical marker used to identify newborns who may have AADC-D, and determine appropriate screening cut-off values.

Approximately 16,000 newborns born in participating hospitals in Liguria will be included in the study. After informed consent is obtained from their parents or legal caregivers, blood samples will be collected using dried blood spot cards as part of the existing regional newborn screening procedures.

The samples will be analyzed using tandem mass spectrometry to measure 3-OMD levels. Samples with positive screening results will be retested. If the result remains positive, genetic testing of the DDC gene will be performed to confirm the diagnosis.

The study will evaluate 3-OMD levels in the neonatal population, establish and periodically refine screening thresholds, and assess the preliminary performance of the screening method. The results are expected to support the development of a reliable newborn screening program for AADC-D in Liguria and facilitate the early identification of affected newborns.

02

Conditions studied

  • Neurology
  • Aromatic Amino Acid Decarboxylase Deficiency
  • Pediatric Neurological Disorder
03

In context

Lead sponsor

Istituto Giannina Gaslini is the lead sponsor of 54 studies on the registry; 35 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 3 Days
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of approximately 16,000 newborns born at participating birth centers in the Liguria region, Italy. Newborns whose parents or legal caregivers have read the study information sheet and provided written informed consent will be eligible for inclusion. Dried blood spot samples will be collected as part of the regional newborn screening program to measure 3-O-methyldopa (3-OMD) levels and identify newborns who may have aromatic L-amino acid decarboxylase deficiency (AADC-D). Positive screening results will undergo repeat testing and, if confirmed, genetic testing of the DDC gene.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newborns born in participating birth centers in the Liguria region, Italy.
  • Written provided by a parent or legal caregiver after reading the study information sheet.

Exclusion criteria

Exclusion Criteria:

  • Absence of written from a parent or legal caregiver.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Development of an Analytical and Post-Analytical Newborn Screening Protocol for Aromatic L-Amino Acid Decarboxylase Deficiency (AADC-D)

    Establishment of an analytical and post-analytical protocol for newborn screening of AADC-D using 3-O-methyldopa (3-OMD) measurement in dried blood spot samples by tandem mass spectrometry.

    Time frame: Two years

  2. Incidence of Aromatic L-Amino Acid Decarboxylase Deficiency (AADC-D) in the Neonatal Population of Liguria, Italy

    Estimation of the incidence of AADC-D based on the number of newborns with genetically confirmed AADC-D identified through screening, relative to the total number of newborns screened.

    Time frame: Two years.

Secondary outcomes

  1. Establishment of Neonatal 3-O-Methyldopa (3-OMD) Reference Values and Screening Cut-off Values

    Determination of reference values for 3-OMD in the neonatal population and optimization of screening cut-off values to reduce the recall rate to below 1%

    Time frame: 2 years

  2. Development of Second-Tier and Confirmatory Biochemical Testing Methods for AADC-D

    Development of second-tier analytical methods to improve the positive predictive value of newborn screening and biochemical confirmatory methods using liquid chromatography-tandem mass spectrometry (LC-MS/MS) on plasma and urine samples.

    Time frame: 2 years

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Dec 2025, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2026
First posted
Oct 16, 2026
StartActual
Aug 17, 2023
Primary completionActual
Dec 31, 2025
CompletionEst.
Dec 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07877714
Lead sponsor
Istituto Giannina Gaslini
Responsible party
Sponsor
First posted
Oct 16, 2026
Start date
Aug 17, 2023
Primary completion
Dec 31, 2025
Completion
Dec 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

Pasquale Striano, PhD
Contact
pasqualestriano@gaslini.org
+39 010 56362564

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion